发明公开
EP1961744A1 BASIC GROUP-CONTAINING COMPOUND AND USE THEREOF
有权
VERBINDUNG MIT BASISCHEN GRUPPEN UND DEREN VERWENDUNG
- 专利标题： BASIC GROUP-CONTAINING COMPOUND AND USE THEREOF
- 专利标题（中）： VERBINDUNG MIT BASISCHEN GRUPPEN UND DEREN VERWENDUNG
-
申请号： EP06832893.9申请日： 2006-11-17
-
公开(公告)号： EP1961744A1公开(公告)日： 2008-08-27
- 发明人: KOKUBO, Masaya , OCHIAI, Hiroshi , TAKAOKA, Yoshikazu , SHIBAYAMA, Shiro
- 申请人： ONO PHARMACEUTICAL CO., LTD.
- 申请人地址： 1-5, Doshomachi 2-chome Chuo-ku Osaka-shi, Osaka 541-8526 JP
- 专利权人： ONO PHARMACEUTICAL CO., LTD.
- 当前专利权人： ONO PHARMACEUTICAL CO., LTD.
- 当前专利权人地址： 1-5, Doshomachi 2-chome Chuo-ku Osaka-shi, Osaka 541-8526 JP
- 代理机构： Henkel, Feiler & Hänzel
- 优先权： JP2005334937 20051118; JP2006049378 20060224
- 国际公布： WO2007058322 20070524
- 主分类号： C07D233/64
- IPC分类号： C07D233/64 ; A61K31/417 ; A61K31/4178 ; A61K31/438 ; A61K31/454 ; A61K31/4725 ; A61K31/496 ; A61K31/55
摘要：
A compound represented by general formula (I):
a salt thereof, a solvate thereof, or a prodrug thereof wherein all symbols are as defined in the specification has an antagonistic activity against CXCR4 and is therefore useful as a preventive and/or therapeutic agent for CXCR4-mediated diseases, for example, inflammatory and immune diseases (for example, rheumatoid arthritis, arthritis, systemic erythematosus, retinopathy, macular degeneration, pulmonary fibrosis, transplanted organ rejection, etc.), allergic diseases, infections (for example, human immunodeficiency virus infection, acquired immunodeficiency syndrome, etc.), psychoneurotic diseases, cerebral diseases, cardiac /vascular disease(for example, arteriosclerosis, myocardial infarction, stenocardia, cerebral infarction, chronic arterial occlusive disease, etc.), metabolic diseases, and cancerous diseases (for example, cancer, cancer metastasis, etc.), a preventive and/or therapeutic agent for cancerous diseases or infections, or an agent for regeneration therapy.
a salt thereof, a solvate thereof, or a prodrug thereof wherein all symbols are as defined in the specification has an antagonistic activity against CXCR4 and is therefore useful as a preventive and/or therapeutic agent for CXCR4-mediated diseases, for example, inflammatory and immune diseases (for example, rheumatoid arthritis, arthritis, systemic erythematosus, retinopathy, macular degeneration, pulmonary fibrosis, transplanted organ rejection, etc.), allergic diseases, infections (for example, human immunodeficiency virus infection, acquired immunodeficiency syndrome, etc.), psychoneurotic diseases, cerebral diseases, cardiac /vascular disease(for example, arteriosclerosis, myocardial infarction, stenocardia, cerebral infarction, chronic arterial occlusive disease, etc.), metabolic diseases, and cancerous diseases (for example, cancer, cancer metastasis, etc.), a preventive and/or therapeutic agent for cancerous diseases or infections, or an agent for regeneration therapy.
公开/授权文献
- EP1961744B1 BASIC GROUP-CONTAINING COMPOUND AND USE THEREOF 公开/授权日：2013-04-17
信息查询
